WAVEMAN · COMPANY

CITR · Citrotech Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

CITR

Name: CitroTech Inc. (CITR) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

CitroTech Inc.

PHARMA & BIOTECH · CHEMICALS & ALLIED PRODUCTS · CIK 0000894556

SEC FILINGS☆ WATCH

INSIDER NET · 180D

-$825.0K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+194.6%

XBRL, annual

NET MARGIN

-1546.9%

CONVERSIONS · 180D

codes C/M, not in net · $2.3M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$825.0K over 180 days

-$825.0K over 90 days

below 59% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

19 funds added or opened last quarter

below 71% of Pharma & Biotech

REVENUE

+194.6% year over year

more than 89% of Pharma & Biotech

MARGIN

-1546.9% net margin

below 92% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

1.0% of shares outstanding short · 9.5 days to cover · settled 2026-07-31

below 72% of Pharma & Biotech

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -32.7%

-32.7%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $825.0K sold by insiders over 180 days, 19 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF MDGL DNA VRTX NUVL INSM

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, CitroTech Inc. insiders sold a net $825.0K of stock across 704 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Conboy Stephen

—

SELL

2026-08-04

275,001.0

$825.0K

Ralston Theodore

President & CEO

BUY

2025-03-20

50.0

$372

Ralston Theodore

President & CEO

BUY

2025-03-20

33.0

$244

Ralston Theodore

—

BUY

2025-03-19

33.0

$238

Ralston Theodore

—

BUY

2025-03-19

83.0

$622

704 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 699 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

VANGUARD CAPITAL MANAGEMENT LLC

486,620.0 sh

$2.7M

FIFTH THIRD BANCORP

235,281.0 sh

$1.3M

GEODE CAPITAL MANAGEMENT, LLC

176,239.0 sh

$973.3K

Lotus Technology Management, LP

750,000.0 sh

$750.0K

Cerity Partners LLC

101,275.0 sh

$559.0K

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

VANGUARD EXTENDED MARKET INDEX FUND

$1.2M POSITION · AS OF 2026-03-31

0.0%

VANGUARD TOTAL STOCK MARKET INDEX FUND

$2.4M POSITION · AS OF 2026-03-31

0.0%

VANGUARD BALANCED INDEX FUND

$45.4K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$2.4M	$808.4K	$520.6K	$62.7K
GROSS PROFIT	—	—	$387.1K	$60.8K
OPERATING INCOME	$-16.5M	$-5.3M	$-10.1M	$-2.9M
NET INCOME	$-36.8M	$-6.9M	$-10.1M	$-2.9M
EPS (DILUTED)	-2.96	-0.82	-0.10	0.00
OPERATING CASH FLOW	$-5.9M	$-1.9M	$-1.2M	$-708.5K
CASH	$6.3M	$775.1K	—	—

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE